Form 4: GRAIL Director Gregory Summe Acquires Deferred Stock Units Valued Over $31,000

GRAIL, Inc. Director Gregory L. Summe acquired 825 deferred stock units in lieu of cash fees, vesting immediately upon grant, signaling increased insider ownership.

Summary

• Gregory L. Summe, a Director of GRAIL, Inc., acquired 825 shares of Common Stock in the form of deferred stock units.
• The transaction occurred on July 15, 2025, with the shares valued at $38.53 per share, which was the closing price on that date.
• The acquisition represents $31,787.67 in cash fees payable to Mr. Summe for his service as a director, converted into equity.
• These deferred stock units were granted under GRAIL's deferred stock program and 2024 Equity Incentive Plan.
• The awards vested immediately upon the grant date.
• Following this transaction, Gregory L. Summe beneficially owns 38,369 shares of GRAIL, Inc. Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by a director, especially in lieu of cash fees and with immediate vesting, generally indicates confidence in the company's future and aligns the director's interests with those of shareholders, which is a positive signal.

Positives

• Director Gregory L. Summe increased his ownership stake in GRAIL, Inc. through the acquisition of deferred stock units, aligning his interests more closely with shareholders.
• The immediate vesting of the 825 deferred stock units indicates strong confidence in the company's future performance.
• The transaction is part of a structured deferred stock program and 2024 Equity Incentive Plan, reflecting a systematic approach to director compensation and retention.

Future Outlook

No explicit future outlook or guidance is provided in this Form 4 filing, as it primarily reports a historical insider transaction.

Industry Context

This Form 4 filing details a routine insider transaction where a director acquires company stock as part of their compensation. In the biotechnology and healthcare industry, such equity-based compensation is common and serves to align the interests of directors and executives with those of shareholders, particularly for companies like GRAIL, Inc. focused on innovative and long-term development in cancer detection.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as deferred stock units, in lieu of cash fees is a common corporate governance standard across various industries, including biotech.
• This approach is similar to compensation structures seen at other precision oncology companies like Exact Sciences (EXAS) or Guardant Health (GH), where equity incentives are a significant component of executive and director remuneration to foster long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The acquisition of 825 deferred stock units by Director Gregory L. Summe in lieu of $31,787.67 in cash fees for his service, based on the company's deferred stock program and 2024 Equity Incentive Plan, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through greater equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

Keywords

GRAIL Inc., GRAL, Gregory Summe, Director, SEC Form 4, Deferred Stock Units, Equity Incentive Plan, Insider Trading, Stock Acquisition, Corporate Governance